Drug Profile
MNX 160
Latest Information Update: 31 Aug 1998
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Macronex; Nonindustrial source
- Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Adult respiratory distress syndrome; Asthma; Cachexia; Diabetes mellitus; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 31 Aug 1998 No-Development-Reported for Adult respiratory distress syndrome in USA (PO)
- 31 Aug 1998 No-Development-Reported for Asthma in USA (PO)
- 31 Aug 1998 No-Development-Reported for Cachexia in USA (PO)